Deregibus

Andrea Deregibus, Padova IT

Patent application number	Description	Published
20110023985	Multilayer tube, particularly for industrial systems for the production and/or treatment of chemical compounds and the like - A multilayer tube for industrial systems for the production and/or treatment of chemical compounds, in fluid form, comprising a plurality of layers, of which at least one internal layer forming the duct for the fluid, an electrically conducting layer external to the internal layer, and a protection and finishing layer of the electrically conducting layer which it covers, forming the outer surface of the multilayer tube.	02-03-2011

Patent application number	Description	Published
20110033523	USE OF MICROVESICLES (MVS) DERIVED FROM STEM CELLS FOR PREPARING A MEDICAMENT FOR ENDO/EPITHELLAL REGENERATION OF DAMAGED OR INJURED TISSUES OR ORGANS, AND RELATED IN VITRO AND IN VIVO METHODS - The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).	02-10-2011

Patent application number	Description	Published
20100233216	USE OF MICROVESICLES (MVS) FOR PREPARING A MEDICAMENT HAVING ADJUVANT ACTIVITY ON ENDOTHELIAL CELL TRANSPLANTATION, PARTICULARLY IN THE TREATMENT OF DIABETES BY PANCREATIC ISLET TRANSPLANTATION, AND RELATED METHOD - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.	09-16-2010